Thrombosis and malignancy: an underestimated problem

Same author

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Science translational medicine·2026

Same author

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Thrombosis research·2026

Same author

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

British journal of haematology·2026

Same author

Correction: Colarusso et al. Role of the AIM2 Inflammasome in Cancer: Potential Therapeutic Strategies. Biomedicines 2025, 13, 395.

Biomedicines·2025

Same author

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Thrombosis and haemostasis·2025

Same author

Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.

BMC bioinformatics·2025

Same journal

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Same journal

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a post-hoc analysis of the RIDTS trial.

Haematologica·2026

Same journal

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Haematologica·2026

Same journal

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026

Same journal

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Same journal

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Haematologica·2026

Related Experiment Videos

Thrombosis and malignancy: an underestimated problem

Related Concept Videos

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

Correction: Colarusso et al. Role of the AIM2 Inflammasome in Cancer: Potential Therapeutic Strategies. <i>Biomedicines</i> 2025, <i>13</i>, 395.

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.

Related Experiment Videos

Thrombosis and malignancy: an underestimated problem

Related Concept Videos

Related Articles

Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.

Coagulopathy in acute promyelocytic leukaemia: Can we better predict and prevent catastrophic bleeding?

Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review.

Correction: Colarusso et al. Role of the AIM2 Inflammasome in Cancer: Potential Therapeutic Strategies. <i>Biomedicines</i> 2025, <i>13</i>, 395.

Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper.

Cancer detection via one-shot learning: integrating gene expression and genomic mutation analysis.

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Incidence and predictors of recurrent venous thromboembolism after isolated distal deep vein thrombosis: a <i>post-hoc</i> analysis of the RIDTS trial.

Philadelphia positive T-acute lymphoblastic leukemia: a Mayo Clinic series.

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphoma.